Michael Sun, PhD: CMC / Manufacturing
Dr. Mike Sun has more than 20 years of experience in the CMC of ADCs, from pre-IND to commercial. Dr Sun’s experience includes leadership roles for multiple companies, most recently as Senior Vice President of CMC for VelosBio, which was acquired by Merck for $2.75B. Prior roles included serving as Vice President of CMC at Silverback Therapeutics and various leadership roles during his 17-year tenure at Seagen.
Dr. Sun participated in the development and submission of more than 30 antibody and ADC INDs and 4 BLAs, including serving as the CMC Lead during development and approval of ADCETRIS and PADCEV. Dr. Sun serves as technical advisor to multiple biotechnology companies developing ADCs.
Dr. Sun holds a Ph.D. in Chemical Engineering from the University of California, Berkeley and a B.S. in Chemical Engineering from the University of Washington.
Gabriele Multhoff, PhD
Gabriele Multhoff currently holds a C3 Professorship in Experimental Radiation Oncology/Radiation Biology at the Department of Radiation Oncology and Radiation Therapy at the Klinikum rechts der Isar, Technical University of Munich (TUM). She is also the Founder and CSO of Multimmune GmbH and is the named inventor on multiple granted patents relating to theranostics based on her discovery of membrane Hsp70 expression on tumor cells.
Prof. Gabriele Multhoff’s research is the development of innovative immunotherapies based on targeting membrane Hsp70 on cancers. Her research led to a randomized, multicenter clinical phase II study for patients with Advanced Stage IIIb non-small cell lung carcinoma (NSCLC) after radiochemotherapy funded by the German Federal Ministry of Education and Research (BMBF) which confirmed the therapeutic potential of such targeted therapeutics.
She also invented a novel ELISA cancer monitoring test (US patent granted) which quantifies levels of exosomal, tumor-derived Hsp70 in the blood of patients.